Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
Go back to Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases| (NASDAQ: TVTX) | Delayed: 55.15 +1.01 (1.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $54.14 | 52 Week High | $ | |||
| Open | $54.65 | 52 Week Low | $ | |||
| Day High | $55.99 | P/E | N/A | |||
| Day Low | $53.75 | EPS | $ | |||
| Volume | 6,587,102 | |||||
